In 1994, Kannourakis reported elevated peripheral blood levels of GM-CSF and IL-3 in MS-LCH patients, recognizing that cytokines in LCH lesions were likely to be released to the circulation (12). The gene discussed is CSF2; the disease is myeloid sarcoma.